Search Within

Heather Jolie Landau

Formats
  1. Meeting Abstract (281)
  2. Journal Article (127)
  3. Research Letter (15)
  4. Book Section (5)
  5. Review (3)
  6. Correspondence (2)
  7. Conference Paper (1)
  8. Editorial (1)
  9. Guidelines (1)
Groups
  1. Bone Marrow Transplant (436)
  2. Center for Hematologic Malignancies (436)
  3. Department of Medicine (436)
  4. Hematologic Malignancies, Division of (436)
  5. Survivorship Research (436)
  6. Myeloma (249)

More Groups

People
  1. Sergio Giralt (263)
  2. Hani Hassoun (224)
  3. David Chung (207)
  4. Alexander Lesokhin (187)
  5. Gunjan Shah (164)
  6. Sham Mailankody (147)

More People

Years
  1. 2025 (14)
  2. 2024 (51)
  3. 2023 (48)
  4. 2022 (42)
  5. 2021 (25)
  6. 2020 (34)

More Years

Publications
  1. Blood (154)
  2. Clinical Lymphoma, Myeloma and Leukemia (53)
  3. Biology of Blood and Marrow Transplantation (48)
  4. Journal of Clinical Oncology (24)
  5. Bone Marrow Transplantation (12)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (166)
  2. Elsevier Inc. (111)
  3. Nature Publishing Group (30)
  4. American Society of Clinical Oncology (25)
  5. Taylor & Francis Group (21)
  6. Ferrata Storti Foundation (8)

More Publishers

Results (436)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Kidney transplantation in AL amyloidosis: Is it time to maximize access?
    Research Letter

    Sathick, I. J.; Rosenbaum, C. A.; Gutgarts, V.; Landau, H.
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
    Journal Article

    Prockop, S.; Doubrovina, E.; Suser, S.; Heller, G.; Barker, J.; Dahi, P.; Perales, M. A.; Papadopoulos, E.; Sauter, C.; Castro-Malaspina, H.; more...
    Journal of Clinical Investigation (2020)

    Fulltext@MSK | Save
  • Pilot study of bortezomib and dexamethasone pre- and post-risk-adapted autologous stem cell transplantation in AL amyloidosis
    Journal Article

    Landau, H.; Lahoud, O.; Devlin, S.; Lendvai, N.; Chung, D. J.; Dogan, A.; Landgren, C. O.; Giralt, S.; Hassoun, H.
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Presalvage international staging system stage and other important outcome associations in CD34(+)-selected allogeneic hematopoietic stem cell transplantation for multiple myelomas
    Journal Article

    Bryant, A. R.; Hilden, P.; Giralt, S.; Chung, D. J.; Maloy, M.; Landau, H.; Landgren, O.; Scordo, M.; Shah, G.; Smith, E. L.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis
    Meeting Abstract

    Sanchez, L.; Landau, H. J.; Rosenbaum, C. A.; Abrahams, A.; Chin, C.; Liotta, B.; Agudo, N.; Ramnath, S.; Hoover, E.; Rahman, H.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Difference in involved and uninvolved free light chain (dFLC) of less than 1mg/DL early post risk adapted melphalan and autologous stem cell transplantation (RA-ASCT) predicts renal response at 1 year in light chain (AL) amyloidosis
    Meeting Abstract

    Purvey, S.; Seier, K.; Devlin, S. M.; Ruiz, J. D.; Maloy, M. A.; Shah, G. L.; Hassoun, H.; Giralt, S. A.; Landau, H. J.
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Results of the phase 3 VITAL study of NEOD001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients
    Meeting Abstract

    Gertz, M. A.; Cohen, A. D.; Comenzo, R. L.; Du Mond, C.; Kastritis, E.; Landau, H. J.; Libby, E. N. 3rd; Liedtke, M.; Merlini, G.; Sanchorawala, V.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Outpatient BEAM using daily etoposide and cytarabine with autologous hematopoietic stem cell transplantation for lymphoma is feasible and decreases inpatient length of stay
    Meeting Abstract

    Cazeau, N.; Cavalier, K.; Bhatt, V.; McElrath, C.; Lestrange, N.; Lachaud-Richard, M.; Inumerables, F.; Andrejko, M.; Batalha, J.; Cohen, A.; more...
    Blood (2019)

    Fulltext@MSK | Save